OBJECTIVE: To evaluate the clinical benefit of Abiraterone acetate plus prednisone (AA + P) withandrogen deprivation therapy in patients with metastatic prostate cancer as a local experience in thePhilippines. MATERIALS AND METHODS: The authors evaluated retrospectively a case series of seven patients receivingandrogen deprivation therapy with high-risk metastatic castration-sensitive prostate cancer (mCSPC)and metastatic castration-resistant prostate cancer (mCRPC) treated with AA + P in a tertiary hospitalfrom April 2019 to October 2020. Disease characteristics, biochemical trend, quality of life evaluationusing the European Organization for Research and Treatment of Cancer Questionnaire (EORTCQLQ-C30 v.3), and adverse events reporting using Common Terminology Criteria for Adverse Events(CTCAE) Version 5.0 were all retrieved from the medical records as outcome measures. RESULTS: Analysis of 18 months period using chart review was done. Five patients showed clinicalimprovement on positive PSA response. Patients also presented with Grade 1-2 adverse events scorebased on CTCAE including hypertension, hepatotoxicity, gastrointestinal symptoms, and electrolyteimbalances. Using the EORTC QLQ-C30 v.3 showed that AA + P provided significant improvementon the overall quality of life, functioning in terms of role, emotional, cognitive and social aspectswith reasonable safety profile and minimal adverse events limited to worsening of gastrointestinalsymptoms from baseline. CONCLUSION The addition of AA + P to androgen deprivation therapy is a suitable option for bothhigh-risk mCSPC and mCRPC exhibiting a significant biochemical, functional and quality of lifeimprovement with reasonable safety profile and limited adverse events in the ‘real-world’ setting, whichis comparable with the findings in other similar studies.